Skip to main content
OpenTrials

Clinical trial condition

Multiple Sclerosis, Relapsing-Remitting

Explore clinical trials studying Multiple Sclerosis, Relapsing-Remitting. Study availability and eligibility vary by location and protocol.

455 public trials 46 recruiting studies
Refine in advanced search Browse all conditions

Multiple Sclerosis, Relapsing-Remitting trial results

Completed

A Study for Tecfidera (Dimethyl Fumarate) Capsules in Korean Participants With Relapsing-Remitting Multiple Sclerosis

NCT05366036

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +5 more
Locations
  • Site #20 Cheonan, Chungcheongnam-do, South Korea
  • Site #15 Ansan, Gyeonggi-do, South Korea
  • Site #08 Bucheon-si, Gyeonggi-do, South Korea
  • Site #09 Goyang-si, Gyeonggi-do, South Korea
View all 20 locations
View Trial Details
Completed

Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409

NCT02255656

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +6 more
Locations
  • Investigational Site Number 1086 Cullman, Alabama, United States
  • Investigational Site Number 1031 Phoenix, Arizona, United States
  • Investigational Site Number 1171 Phoenix, Arizona, United States
  • Investigational Site Number 1090 Tucson, Arizona, United States
View all 131 locations
View Trial Details
Completed

Real World Effectiveness of Natalizumab Extended Interval Dosing in a French Cohort

NCT04580381

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +5 more
Locations
  • Department of Neurology, CHU Bobigny-Avicenne Bobigny, France
  • Department of Neurology, CHU de Caen Caen, France
  • Department of Neurology, Percy Military Hospital Clamart, France
  • Department of Neurology, CHU Nice Nice, France
View Trial Details
Completed

A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)

NCT02861014

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +5 more
Locations
  • St George Hospital Kogarah, New South Wales, New South Wales, Australia
  • Hospital Erasme Brussels, Belgium
  • Cliniques Universitaires St-Luc Brussels, Belgium
  • UZ Antwerpen Edegem, Belgium
View all 163 locations
View Trial Details
Completed

A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo

NCT01067521

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +6 more
Locations
  • Teva Investigational Site 1332 Birmingham, Alabama, United States
  • Teva Investigational Site 1327 Gilbert, Arizona, United States
  • Teva Investigational Site 1311 Phoenix, Arizona, United States
  • Teva Investigational Site 1326 Fullerton, California, United States
View all 176 locations
View Trial Details

Related conditions